Zilbrysq is a medication approved for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) [1]. It is a bispecific antibody designed to target both the CD19 antigen on cancer cells and the CD3 receptor on T-cells, thereby redirecting T-cells to kill cancer cells [1][2].
What is Zilbrysq approved for?
Zilbrysq (epcoritamab-bysp) received accelerated approval from the U.S. Food and Drug Administration (FDA) in May 2023 for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) [1]. This indication is based on response rate, and continued approval for this condition may be contingent upon verification and description of clinical benefit in confirmatory trials [1].
How does Zilbrysq work?
Zilbrysq is a type of immunotherapy called a bispecific T-cell engager [1][2]. It works by binding to two targets simultaneously: CD19, a protein found on the surface of most B-cells, including cancerous B-cells in B-ALL, and CD3, a protein found on the surface of T-cells [1][2]. This dual binding brings T-cells into close proximity with CD19-positive cancer cells, activating the T-cells to destroy the malignant B-cells [1][2].
What is the clinical data supporting Zilbrysq's approval?
The FDA's accelerated approval of Zilbrysq was based on the results of a single-arm, open-label, multi-center clinical trial [1]. This trial evaluated the efficacy of Zilbrysq in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia [1]. The primary endpoint was the overall response rate (ORR) [1].
What are the common side effects of Zilbrysq?
Common side effects reported in clinical trials for Zilbrysq include infections, infusion-related reactions, and fatigue [1]. As with other T-cell engagers, patients treated with Zilbrysq are at risk for cytokine release syndrome (CRS), which is a potentially serious adverse reaction [1].
What is cytokine release syndrome (CRS)?
Cytokine release syndrome (CRS) is a systemic inflammatory response that can occur after treatment with certain immunotherapies, including T-cell engagers like Zilbrysq [1][2]. It happens when the activated immune cells release large amounts of cytokines, leading to a cascade of inflammatory effects in the body [2]. Symptoms of CRS can range from mild, such as fever and chills, to severe, including low blood pressure, difficulty breathing, and organ dysfunction [2]. Patients receiving Zilbrysq should be monitored for signs and symptoms of CRS [1].
When does Zilbrysq's patent expire?
Information regarding specific patent expiry dates for Zilbrysq is not readily available through general drug information sources. Patent landscapes for medications are complex and can involve multiple patents covering the drug substance, formulations, and methods of use [3]. For detailed patent information, resources like DrugPatentWatch.com can provide comprehensive patent data, including expiry dates and patent litigation [3].
Who makes Zilbrysq?
Zilbrysq is manufactured by AbbVie Inc. [1].